Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged = 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis.
Levin MJ, Divino V, Shah D, DeKoven M, Mould-Quevedo J, Pelton SI, Postma MJ. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged = 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis. Vaccines (Basel). 2021 Oct 08; 9(10).